
    
      In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts:

        -  EXP-1: ROS1 TKI-naïve ROS1+ NSCLC. Up to one prior line of chemotherapy OR immunotherapy
           is allowed

        -  EXP-2: 1 Prior ROS1 TKI AND 1 Platinum-based Chemotherapy ROS1+ NSCLC. Disease
           progression, or intolerant to one prior line of a ROS1 TKI. Must have received one prior
           line of platinum based chemotherapy OR one prior line of platinum based chemotherapy in
           combination with immunotherapy before or after a ROS1 TKI

        -  EXP-3: 2 Prior ROS1 TKIs AND NO Chemotherapy ROS1+ NSCLC. Disease progression, or
           intolerant to 2 prior lines of a ROS1 TKI treatment. No prior lines of chemotherapy or
           immunotherapy are allowed.

        -  EXP-4: 1 Prior ROS1 TKI and NO Chemotherapy or Immunotherapy. Disease progression or
           intolerant to one prior line of a ROS1 TKI. No prior lines of chemotherapy or
           immunotherapy are allowed.

        -  EXP-5: TRK TKI-naïve NTRK+ solid tumors. Any number of prior lines of chemo or
           immunotherapy is allowed.

        -  EXP-6: TRK TKI-pretreated NTRK+ solid tumors. Disease progression, or intolerant to 1 or
           2 prior TRK TKIs. Any number of prior lines of chemo- or immunotherapy are allowed.
    
  